This product is a RPMI 1788 B cell engineering tool based on the Nanoparticles (Hyaluronic acid/ RHAMM, CD44) delivery system and CRISPR-based (SHS-321-tracr RNA-Cas9-RS-1 ) genome editor.
| Host Cell | RPMI 1788 |
| Target | AFP |
| Insert Clone | 50.11.8 |
| Safe Harbor Sites (SHS) | SHS-321 |
| gRNA | tracr RNA |
| Nuclease | Cas9 |
| Enhancer | RS-1 (RAD51-stimulatory compound 1) |
| Targeting Strategy | Enzyme responsive, time-dependent |
| Insertion sites | Nonhomologous target sites |
| Vehicles | Nanoparticles |
| Ligand/Receptor | Hyaluronic acid/ RHAMM, CD44 |
| Active Agents | AntimiR-21, doxorubicin (DOX) |
| Particle Size | 10-500 |
| Charge (mv) | −15 to -185 |
| Total Atom Count | ~20,000,000 |
| Surface Atoms (%) | ~4 |
| Specific Surface Area (m2/g) | ~8 |
| Vector Type | VSV |
| Vector Name | BCpCDH7 |
| Targeting Diseases | Breast cancer; Colon cancer; Lung cancer; Ovarian cancer |
Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.